Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Key Considerations for the Management of Pediatric Hodgkin Lymphoma (JA copy)
The NCCN Guidelines for pediatric Hodgkin lymphoma were created to help define optimal clinical care for these patients. Continuing education on emerging developments in this arena will help ensure that clinicians are aware of how best to incorporate these strategies, which may enhance care and outcomes for patients with pediatric Hodgkin lymphoma.
NCCN Guidelines® Insights - Hodgkin Lymphoma, Version 2.2022

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL.

Recorded Presentation from the NCCN Pharmacy Updates: Emerging Strategies for Pediatric Hodgkin Lymphoma Treatment
It is important for pharmacists to understand the long-term side effects of both systemic treatment and radiation in order to provide in-depth patient counseling, as well as appropriate therapy recommendations to the multidisciplinary team.
NCCN Pharmacy Updates: Emerging Strategies for Pediatric Hodgkin Lymphoma Treatment
It is important for pharmacists to understand the long-term side effects of both systemic treatment and radiation in order to provide in-depth patient counseling, as well as appropriate therapy recommendations to the multidisciplinary team.
Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Key Considerations for the Management of Pediatric Hodgkin Lymphoma
The NCCN Guidelines for pediatric Hodgkin lymphoma were created to help define optimal clinical care for these patients. Continuing education on emerging developments in this arena will help ensure that clinicians are aware of how best to incorporate these strategies, which may enhance care and outcomes for patients with pediatric Hodgkin lymphoma.
New NCCN Guidelines for Pediatric Cancers: Key Considerations for the Management of Pediatric Hodgkin Lymphoma
The NCCN Guidelines for pediatric Hodgkin lymphoma were created to help define optimal clinical care for these patients. Continuing education on emerging developments in this arena will help ensure that clinicians are aware of how best to incorporate these strategies, which may enhance care and outcomes for patients with pediatric Hodgkin lymphoma.
Controversies in the Management of Early-Stage Hodgkin Lymphoma
Patients with early-stage Hodgkin lymphoma (HL) often experience high cure rates with current therapeutic measures which include chemotherapy alone or chemotherapy and radiotherapy; however, late effects due to treatment-related toxicity is of significant concern. Emerging studies are shedding light on these controversies and clinicians are challenged to remain abreast of these developments to optimize treatment of patients with early-stage HL. 
Updates in Treatment Strategies for Hodgkin Lymphoma

Most patients with Hodgkin lymphoma experience favorable outcomes after therapy, but some patients experience relapse and many others experience treatment-related toxicities. To combat these issues, it is important to have therapies that are effective and less toxic.

Emerging Options for the Management of Relapsed/Refractory Hodgkin Lymphoma

Patients with relapsed or refractory Hodgkin lymphoma (R/R HL) have limited therapeutic options, which are further narrowed once they become unresponsive to stem cell transplant.

Updates to Front-line Therapy in Hodgkin Lymphoma

Patients with advanced Hodgkin lymphoma (HL) have limited options.

Pages

Subscribe to RSS - Hodgkin Lymphoma